Coloplast A/S Series B,

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.
  • TickerCOLO B
  • ISINDK0060448595
  • ExchangeNasdaq Nordic Copenhagen
  • SectorHealth Care Equipment & Services
  • CountryDenmark

Analysts

Expert Corporate Governance Service (ECGS)

Coloplast - AGM 05 December 2019

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEMS 4 and 5.2 the board of directors  seeks approval for the Company's remuneration report (ITEM 4) and remuneration policy (ITEM 5.2). Although ECGS strongly welcomes the first separate remuneration report, Coloplast's remuneration structure is NOT considered to be in line with its guidelines. Accordingly, ECGS recommends to vote OPPOSE to both agenda items. Under ITEM 6.1 it is proposed to (re-)appoint Mr. Lars Søren Rasmussen as Chairman of ...

Nurhayati Wan

Coloplast A/S

Nurhayati Wan

Coloplast A/S

Rune Majlund Dahl

Coloplast (Sell, TP: DKK700.00) - Organic growth and margin softness

Q4 delivered c8% group organic growth YOY, in line with consensus expectations with a soft EBIT margin at 32% before special items of DKKc400m in additional provisions for the MESH litigation. While the 2019/20 guidance for 7–8% organic growth was as we expected, the low end is most likely in our view, with flexibility on incremental investments to reach the guided c31% EBIT margin. With only minor estimate changes we reiterate our SELL and DKK700 target price.

Nurhayati Wan

Coloplast A/S

Nurhayati Wan

Coloplast A/S

Rune Majlund Dahl

Coloplast (Sell, TP: DKK700.00) - Organic growth and margin softness

Q4 delivered c8% group organic growth YOY, in line with consensus expectations with a soft EBIT margin at 32% before special items of DKKc400m in additional provisions for the MESH litigation. While the 2019/20 guidance for 7–8% organic growth was as we expected, the low end is most likely in our view, with flexibility on incremental investments to reach the guided c31% EBIT margin. With only minor estimate changes we reiterate our SELL and DKK700 target price.

Bengt Jonassen ...
  • Haakon Amundsen
  • Jannick Lindegaard Denholt
  • Karl Fredrik Schjøtt-Pedersen
  • Magnus Andersson
  • Morten Raunholt Eismark

Talking Points - EQT (Hold): Addicted to performance

Lundbeck (Hold) Post-results comment: All eyes on 2020 progress and execution Strong top-line growth and margin expansion Initiating coverage with HOLD - TP of SEK 100

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Coloplast - CMD to reveal next phase of LT prospects

‘19/20 looks to be solidly steady despite some headwind EBIT guidance, however, reveals underlying leverage Quality costs; however, short-term upside seems limited

1 director bought

A director at Coloplast As bought 36,500 shares at 765.701DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Alexander Aukner ...
  • Christoffer Wang Bjørnsen
  • Frank Maaø
  • Joachim Gunell
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Hoang Nguyen
  • Martin Huseby Karlsen
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl

Northern Lights

Jon Berggren ...
  • Karl-Johan Bonnevier
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Alexander Aukner ...
  • Joachim Gunell
  • Karl-Johan Bonnevier
  • Mats Bye
  • Nicolay Dyvik
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Niclas Gehin ...
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Tomi Railo

Northern Lights

Alexander Aukner ...
  • Frank Maaø
  • Jon Masdal
  • Marius Knudssøn
  • Martin Hoang Nguyen
  • Nicolay Dyvik
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

COLOPLAST A/S sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of COLOPLAST A/S (DK), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 10, 2019, the closing price was DKK 772.20 and its target price was estimated at DKK 722.31.

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Nurhayati Wan

Coloplast

Expert Corporate Governance Service (ECGS)

Coloplast - AGM 05 December 2019

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEMS 4 and 5.2 the board of directors  seeks approval for the Company's remuneration report (ITEM 4) and remuneration policy (ITEM 5.2). Although ECGS strongly welcomes the first separate remuneration report, Coloplast's remuneration structure is NOT considered to be in line with its guidelines. Accordingly, ECGS recommends to vote OPPOSE to both agenda items. Under ITEM 6.1 it is proposed to (re-)appoint Mr. Lars Søren Rasmussen as Chairman of ...

Coloplast – Proxinvest Corporate Governance Rating ® : E

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Coloplast - 2018, December 5th

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting. On November 1, 2018, the Company announced that Mr. L.S. Rasmussen will resign from his position as CEO to become the new Chairman of the board of directors as of this AGM. Mr. Rasmussen will be succeeded by Executive Vice President - Mr. Kristian Villumsen - as of the same date.   Under ITEM 5.1, it is proposed to re-appoint Mr. N.P. Louis Hansen as Vice Chairman of the board of directors. Although ECGS has no (major) concerns over the re-appointment...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.Under ITEM...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch